742 related articles for article (PubMed ID: 33759318)
1. Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.
Haghjoo M; Golipra R; Kheirkhah J; Golabchi A; Shahabi J; Oni-Heris S; Sami R; Tajmirriahi M; Saravi M; Khatami M; Varnasseri M; Kiarsi M; Hejazi SF; Yousefzadeh Rahaghi M; Taherkhani M; Ashraf H; Keshmiri MS; Akbarzadeh MA; Bozorgi A; Mottaghizadeh F; Hedayat B; Heidarali M; Hajhossein Talasaz A
Int J Clin Pract; 2021 Jul; 75(7):e14182. PubMed ID: 33759318
[TBL] [Abstract][Full Text] [Related]
2. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
[TBL] [Abstract][Full Text] [Related]
3. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
[TBL] [Abstract][Full Text] [Related]
4. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
6. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.
Russo V; Carbone A; Mottola FF; Mocerino R; Verde R; Attena E; Verde N; Di Micco P; Nunziata L; Santelli F; Nigro G; Severino S
Front Pharmacol; 2020; 11():582348. PubMed ID: 33132915
[TBL] [Abstract][Full Text] [Related]
7. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
8. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
9. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
[TBL] [Abstract][Full Text] [Related]
10. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
12. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.
Agstam S; Yadav A; Kumar-M P; Gupta A
Indian Pacing Electrophysiol J; 2021; 21(1):36-43. PubMed ID: 33075484
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
[TBL] [Abstract][Full Text] [Related]
15. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Carron J; Sharif Z; Hussein H; Kennedy M; McAdam B; Sheahan R
Ir J Med Sci; 2021 Feb; 190(1):403-409. PubMed ID: 32627127
[TBL] [Abstract][Full Text] [Related]
16. QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection.
El Nekidy WS; Almuti K; ElRefaei H; Atallah B; Mohammad LM; AlMahmeed W; Badr M; Abdallah K; Hamed F; Mallat J
J Cardiovasc Pharmacol Ther; 2022; 27():10742484211069479. PubMed ID: 35006023
[TBL] [Abstract][Full Text] [Related]
17. Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Aslam W; Lamb CR; Ali N
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33762277
[TBL] [Abstract][Full Text] [Related]
18. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
[TBL] [Abstract][Full Text] [Related]
19. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Ryan K; Benz P; Zosel A; Farkas A; Theobald J
Cardiovasc Toxicol; 2022 Sep; 22(9):866-877. PubMed ID: 35930218
[TBL] [Abstract][Full Text] [Related]
20. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
